Michael Boone, MD
Ophthalmology · Visalia, CANPI 1467494203
Payments from drug & device makers
Across 156 payments — averaging $159.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$14K
- Glaukos Corporation$9K
- Alcon Research LLC$350
- Sight Sciences, Inc.$206
- Rxsight Inc$163
- Bausch & Lomb Americas Inc.$144
- plus $851 from 13 others
What the payments were for
- Consulting fees$10,05040%
- Speaking & faculty fees$4,55018%
- Travel & lodging$3,98516%
- Food & beverage$6,20425%
- Education$300%
- Gifts$390%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 87 | $14,468 |
| Glaukos Corporation | 18 | $8,677 |
| Alcon Research LLC | 1 | $350 |
| Sight Sciences, Inc. | 7 | $206 |
| Rxsight Inc | 3 | $163 |
| Bausch & Lomb Americas Inc. | 3 | $144 |
| Aerie Pharmaceuticals, Inc. | 4 | $141 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $131 |
| Omeros Corporation | 7 | $122 |
| Amgen | 4 | $68 |
| Biotissue Holdings Inc. | 2 | $57 |
| Mallinckrodt Hospital Products Inc. | 2 | $53 |
| Rayner Intraocular Lenses Limited | 3 | $49 |
| Oyster Point Pharma, Inc. | 3 | $48 |
| AbbVie(2 entities) | 2 | $40 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Sun Pharmaceutical Industries Inc. | 2 | $38 |
| Tarsus Pharmaceuticals, Inc. | 2 | $34 |
| Carl Zeiss Meditec, Inc. | 1 | $32 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARGOS$6,997
- Travoprost Intraocular Implant - iDose$5,811
- Clareon$4,500
- LenSx$1,020
- Wavelight Refractive Suite$734
- Unity$734
- Voyager DSLT$734
- iStent inject Trabecular Micro-Bypass Stent System$362
- iDoseTR$263
- Rocklatan$246
- KXL System$175
- PHOTREXA CROSS-LINKING KIT$175
- iStent Trabecular Micro-Bypass System Model iS3$141
- AcrySof$137
- iStent Trabecular Micro-Bypass Stent System$125
- Rhopressa$124
- Centurion$121
- iAccess Precision Blade$114
- RXSIGHT CONTACT LENS$114
- RXSIGHT INJECTOR CARTRIDGE$114
How this compares
$24,858 in reported general payments places this provider in the 85th percentile of 2,513 ophthalmology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 78 | $83,186 |
| LumiganBimatoprost | 79 | $32,439 |
| MieboPerfluorohexyloctane/Pf | 27 | $23,869 |
| XiidraLifitegrast | 15 | $20,228 |
| Travoprost | 64 | $12,604 |
| Restasis MultidoseCyclosporine | 16 | $12,331 |
| RocklatanNetarsudil Mesylat/Latanoprost | 27 | $10,139 |
| Cyclosporine | 23 | $8,940 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 26 | $7,703 |
| ProlensaBromfenac Sodium | 13 | $4,374 |
| Prednisolone Acetate | 92 | $3,035 |
| Latanoprost | 310 | $2,677 |
| Brinzolamide | 14 | $2,547 |
| Loteprednol Etabonate | 17 | $2,211 |
| Timolol Maleate | 78 | $1,690 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Restasis Multidose | $40 | $127,956173 claims |
| Bausch & Lomb Americas Inc.Miebo, Xiidra | $144 | $44,09842 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $141 | $10,13927 claims |
| AlconSimbrinza | $14,468 | $7,70326 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $131 | $6,58530 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,513 ophthalmology providers in California.
Other ophthalmology in Visalia
- Nisha AcharyaSan Francisco$33M
- David WirtaNewport Beach$18.4M
- Michael IpPasadena$10.2M
- Raymond DouglasBeverly Hills$9.7M
- Sherif El HaraziGlendale$9.2M
- Daniel SchwartzSan Francisco$8M
- Nikolas Londonla Jolla$6.1M
- Michael BerlinWest Hollywood$5.7M
- Steven JacobsonLos Angeles$4.7M
- Peter WinArcadia$4.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.